BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances

BridgeBio Oncology Therapeutics, Inc.

Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).
Cash and equivalents $425.5M; expected to fund operations into 2028.
R&D expenses Q4 $38.1M (vs $19.5M); G&A $5.3M (vs $2.3M); increases driven by clinical and manufacturing.
BBO-8520 monotherapy 65% ORR in KRAS G12C NSCLC; BBO-11818 first confirmed PR in PDAC; BBO-10203 no hyperglycemia.
Clinical data readouts across all three programs expected in H2 2026; internal combinations opening later in 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BridgeBio Oncology Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Oncology Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.